- Home
- ARCT
as 07-26-2024 4:00pm EST
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 602.7M | IPO Year: | N/A |
| Target Price: | $62.83 | AVG Volume (30 days): | 558.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.52 - $45.00 | Next Earning Date: | 08-05-2024 |
| Revenue: | $124,526,000 | Revenue Growth: | -55.69% |
| Revenue Growth (this year): | 11.19% | Revenue Growth (next year): | 16.86% |
Stock Insider Trading Activity of Arcturus Therapeutics Holdings Inc. (ARCT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SASSINE ANDY | ARCT | Chief Financial Officer | Jun 12 '24 | Sell | $32.03 | 50,000 | $1,601,500.00 | 220,526 | SEC Form 4 |
| Chivukula Pad | ARCT | Chief Scientific Officer & COO | Jun 5 '24 | Sell | $45.00 | 114 | $5,130.00 | 447,334 | SEC Form 4 |
| Chivukula Pad | ARCT | Chief Scientific Officer & COO | Jun 3 '24 | Sell | $40.01 | 26,000 | $1,040,234.00 | 447,448 | SEC Form 4 |
| Chivukula Pad | ARCT | Chief Scientific Officer & COO | Mar 25 '24 | Sell | $35.02 | 17,435 | $610,573.70 | 473,448 | SEC Form 4 |
| Chivukula Pad | ARCT | Chief Scientific Officer & COO | Mar 19 '24 | Sell | $35.01 | 8,565 | $299,839.24 | 490,883 | SEC Form 4 |
| Chivukula Pad | ARCT | Chief Scientific Officer & COO | Nov 1 '23 | Sell | $18.72 | 5,000 | $93,601.50 | 499,448 | SEC Form 4 |
Latest Arcturus Therapeutics Holdings Inc. News
ARCT Breaking Stock News: Dive into ARCT Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
MT Newswires
25 days ago
Arcturus Therapeutics Updates Ornithine Transcarbamylase Deficiency, Cystic Fibrosis Programs
Business Wire
25 days ago
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
Business Wire
a month ago
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 06/17/2024
GuruFocus.com
a month ago
Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)
MT Newswires
a month ago
Arcturus Therapeutics Holdings Insider Sold Shares Worth $1,601,500, According to a Recent SEC Filing
MT Newswires
2 months ago
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Compare ARCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARCT Arcturus Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.